<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053622</url>
  </required_header>
  <id_info>
    <org_study_id>16542</org_study_id>
    <secondary_id>I6T-MC-AMAL</secondary_id>
    <secondary_id>2016-003584-18</secondary_id>
    <nct_id>NCT03053622</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab (LY3074828) Injection in Healthy Participants</brief_title>
  <official_title>A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to compare how much mirikizumab, in two different formulations, is&#xD;
      absorbed into the bloodstream and how long the body takes to get rid of it, when given as an&#xD;
      injection under the skin or into the veins. Side effects of the injection will be collected.&#xD;
      Each participant will be in the study for about 18 weeks, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">November 11, 2017</completion_date>
  <primary_completion_date type="Actual">November 11, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Mirikizumab</measure>
    <time_frame>Baseline to at least 29 days following administration of mirikizumab on Day 1 of each study period</time_frame>
    <description>PK: AUC of Mirikizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of Mirikizumab</measure>
    <time_frame>Baseline to at least 29 days following administration of Mirikizumab on Day 1 of each study period</time_frame>
    <description>PK: Cmax of Mirkizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of Cmax (Tmax) of Mirikizumab</measure>
    <time_frame>Baseline to at least 29 days following administration of Mirikizumab on Day 1 of each study period</time_frame>
    <description>PK: Tmax of Mirikizumab</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mirikizumab Test Subcutaneous (SC) 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab test formulation given as a single injection under the skin in healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Test SC 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab test formulation given as two injections under the skin in healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Test Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab test formulation given as an infusion into the vein in healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirikizumab Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirikizumab reference formulation given as three injections under the skin in healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mirikizumab Test</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab Test SC 2</arm_group_label>
    <arm_group_label>Mirikizumab Test Subcutaneous (SC) 1</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mirikizumab Test</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Mirikizumab Test Intravenous (IV)</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mirikizumab Reference</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab Reference</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a screening body mass index (BMI) of greater than 18 and less than or equal to 32&#xD;
             kilograms per meter squared (kg/mÂ²), inclusive&#xD;
&#xD;
          -  Have medical test results that are acceptable for the study&#xD;
&#xD;
          -  Must be willing to make oneself available for the whole study and be willing to follow&#xD;
             study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently participating or recently participated in a clinical trial or any other&#xD;
             type of medical research judged to be incompatible with this study&#xD;
&#xD;
          -  Have known allergies to compounds or drugs similar to Mirikizumab&#xD;
&#xD;
          -  Have previously participated or withdrawn from this study&#xD;
&#xD;
          -  Have or used to have health problems or medical test results that, in the opinion of&#xD;
             the doctor, could make it unsafe to participate, or could interfere with understanding&#xD;
             the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirikizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

